All In Biotech

NDA 207026 · Vantive US Hlthcare

Phoxillum Bk 4/2.5 In Plastic Container

Calcium Chloride, Magnesium Chloride, Potassium Chloride, Sodium Bicarbonate, Sodium Chloride, Sodium Phosphate · Injection

Orphan

Last checked: Nov 20, 2026Latest source record: May 2, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2015

Jan 13, 2015

Approved uses

1

Original approval plus efficacy supplements

Registered trials

9,299

2,122 Phase 3, 968 recruiting

FAERS reports

12

6 serious, 4 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect May 31, 2025.

PRISMASOL and PHOXILLUM solutions are indicated in pediatric and adult patients for use as a replacement solution in Continuous Renal Replacement Therapy (CRRT) to replace plasma volume removed by ultrafiltration and to correct electrolyte and acid-base imbalances. They may also be used in case of drug poisoning when CRRT is used to remove dialyzable substances. PRISMASOL and PHOXILLUM solutions are indicated: • As a replacement solution in Continuous Renal Replacement Therapy (CRRT) and in case of drug poisoning when CRRT is used to remove dialyzable substances ( 1 )

Mechanism: PRISMASOL and PHOXILLUM solutions are pharmacologically inactive. The electrolyte concentrations in the solutions are chosen to restore plasma levels to clinically desired concentrations or maintain plasma levels at the desired concentrations. PRISMASOL and PHOXILLUM solutions are used as replacement solution to replace water and electrolytes removed during hemofiltration and hemodiafiltration. Bicarbonate (or precursor lactate) in the solution is used as an alkalinizing buffer to restore acid-base balance to a clinically desirable level.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

2 products under this application
  • PHOXILLUM BK 4/2.5 IN PLASTIC CONTAINER · CALCIUM CHLORIDE 3.68GM/1000ML; MAGNESIUM CHLORIDE 3.05GM/1000ML; POTASSIUM CHLORIDE 0.314GM/1000ML ; SODIUM BICARBONATE 3.09GM/1000ML; SODIUM CHLORIDE 6.34GM/1000ML; SODIUM PHOSPHATE 0.187GM/1000ML (5000ML) · INJECTABLE, INJECTION · Prescription
  • PHOXILLUM B22K 4/0 IN PLASTIC CONTAINER · CALCIUM CHLORIDE N/A/1000ML; MAGNESIUM CHLORIDE 3.05GM/1000ML; POTASSIUM CHLORIDE 0.314GM/1000ML; SODIUM BICARBONATE 2.21GM/1000ML; SODIUM CHLORIDE 6.95GM/1000ML; SODIUM PHOSPHATE 0.187GM/1000ML (5000ML) · INJECTABLE, INJECTION · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Chloride" as an intervention, any sponsor and status, largest first.

All 9,299 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • hypotension3
  • blood phosphorus increased2
  • general physical health deterioration2
  • septic shock2
  • abdominal pain1
  • acute lymphocytic leukaemia recurrent1
  • blood glucose decreased1
  • blood potassium increased1
  • cardiogenic shock1
  • cardiopulmonary failure1
  • confusional state1
  • cytokine release syndrome1

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20173
20183
20192
20242
20251
20261

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 4,091 on PubMed

Sponsor: Vantive US Hlthcare · Also marketed as Phoxillum B22k 4/0 In Plastic Container

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.